Atezolizumab is primarily used in the treatment of various types of cancer. It is an immunotherapy drug that works by targeting the PD-L1 protein, which helps cancer cells evade the immune system. By blocking PD-L1, atezolizumab enables the immune system to recognize and attack cancer cells more effectively. It is commonly prescribed for advanced or metastatic urothelial carcinoma, non-small cell lung cancer (NSCLC), and triple-negative breast cancer. Additionally, it is used in combination with other therapies, such as chemotherapy or targeted drugs, to enhance its efficacy. Atezolizumab has shown significant promise in improving survival rates and quality of life for patients with these cancers.